Novo Nordisk Announces $2.3 Billion Investment to Expand Danish Manufacturing Facility for Chronic Disease Therapies

Intelligent Finance APP learned that Danish pharmaceutical company Novo Nordisk (NVO.US) plans to invest 15.9 billion Danish kroner (approximately 2.3 billion US dollars) in Denmark to expand production scale, providing greater production capacity for its future product portfolio to meet the growing therapeutic demand.

The expansion will cover an area of approximately 65,000 square meters, and the new production line is expected to be operational by early 2029. This expansion project does not involve its obesity and diabetes drugs. The company stated that this investment will ensure the continuous development of its late-stage drug research and development and is also expected to create 340 new jobs. The company plans to produce drugs for treating serious chronic diseases.

The global obesity market is expected to experience explosive growth. According to Bloomberg Intelligence, sales of weight-loss drugs are projected to reach $44 billion by 2030. This expansion plan can help Novo Nordisk address product supply issues and ensure the company's expansion needs are met.